Search

everythinglearnresearchcommunity

for

Search:↓

The conclusion is that oral contraceptives and antiandrogens can treat hirsutism and acne in women with cutaneous hyperandrogenism, but more research is needed for effective treatments, especially for hair loss.

The French Endocrine Society suggests diagnosing PCOS with two of three signs, recommends lifestyle changes and clomiphene for treatment, and calls for more research on certain treatments and tests.

Some women with PCOS have CYP21 mutations and IRS1 variants, but these genetic factors are not major contributors to PCOS.

About 8.5% of women in Salvador, Brazil, have Polycystic Ovary Syndrome.

Hirsutism can be caused by various conditions besides PCOS, and it's important to treat the underlying issue and manage symptoms with medication and cosmetic approaches.

Insulin-lowering medications show promise for PCOS symptoms but can't be the main treatment yet due to limited long-term research.

Reproductive factors can increase hypertension risk and affect cardiovascular health.

Metformin should be used for PCOS mainly in those with glucose intolerance, and has limited benefits for infertility or hirsutism.

More PDCD4 is linked to obesity, insulin problems, and cell death in ovaries for those with polycystic ovary syndrome.

New treatments for PCOS focus on insulin resistance and reducing testosterone levels, along with traditional hormone therapies.

The research found different metabolism changes in PCOS patients and suggested new potential markers for diagnosing PCOS with or without insulin resistance.

Teens with PCOS and a mom with PCOS have higher insulin resistance and lower adiponectin levels, which could signal early metabolic problems.

PCOS may start before birth, involves metabolic issues, and can be treated with drugs like metformin and lifestyle changes.

Both types of oral contraceptives improved symptoms and hormone levels in women with PCOS.

Researchers found potential urine markers for polycystic ovary syndrome, including testosterone-glucuronide and 11α-hydroxyprogesterone, which may help diagnose the condition.

The document suggests a new model for evaluating public research that better captures the full value of knowledge creation and use, using PCOS research as an example.

Many young Australian women think they have PCOS, but only a few are diagnosed correctly, causing unnecessary worry.

The N363S gene variant does not cause higher adrenal androgen levels in women with polycystic ovary syndrome.

The document concludes that PCOS has a strong genetic component, but more research is needed to fully understand the specific genes involved.

Primary care for PCOS focuses on lifestyle changes, medication based on symptoms, and mental health, with diabetes screening and specialist referral for severe cases.

Different diagnostic criteria greatly affect PCOS diagnosis rates in teenagers.

A certain gene variant may increase the risk of polycystic ovary syndrome in Chinese women.

Insulin resistance is common in PCOS patients and linked to obesity and increased cardiovascular risk.

Iraqi women with PCOS often have higher testosterone levels and obesity.

The document concludes that hormonal biomarkers are key for diagnosing hyperandrogenemia in women and hypogonadism in men.

Skin diseases linked to insulin resistance should be managed to prevent diabetes and reduce heart disease risk.

The study concluded that androstendione and DHEA are important for diagnosing high male hormone levels in women with excessive hair growth.

Women with congenital adrenal hyperplasia have lower fertility, but with proper treatment, they can conceive successfully.

Combination therapy with oral contraceptives and spironolactone improves hair growth, menstrual issues, and acne in women with PCOS.

Young women with nonclassic congenital adrenal hyperplasia may experience worse sexual function and mild depression compared to healthy women.